E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS). (Also known as Benign Rolandic Epilepsy.) |
|
E.1.1.1 | Medical condition in easily understood language |
This epilepsy affects children about 3 to 10 years old. It is associated with mild memory and learning problems. It is called ‘benign’ because seizures are infrequent and children grow out of it. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10070530 |
E.1.2 | Term | Benign rolandic epilepsy |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The overall research objective is to investigate the relationships between interictal epileptiform discharges (abnormal electrical activity in the brain), sleep quality, and consolidation of learning in children with untreated Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS).
The specific research questions are:
1. Is there an association between indices of sleep quality and strength of nocturnal vs. daytime Consolidation of Learning in children with untreated BECCTS?
2. Does treatment of BECCTS lead to the following changes relative to placebo: a. Abolition of Interictal Epileptic Discharges (IEDs) during slow wave sleep (SWS)? b. Improved sleep quality (increased efficiency, reduced number of awakenings, density of sleep spindles and %REM and %SWS)? c. Improved Consolidation of Learning (CoL)? |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria: -Male and female children 6–16 years of age -Within 6 months of diagnosis with BECCTS and the onset of symptoms -With clinical EEG characteristic consistent with typical BECCTS [16] -With no current or prior treatment for BECCTS -Signed informed (parental) consent.
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria: -Inability to comply with assessments -Any serious intercurrent illness or uncontrolled disease which could compromise participation in the study -With contraindications for treatment with sulthiame: -History of hypersensitivity to sulphonamides -History of acute porphyria -History of hyperthyroidism -History of arterial hypertension -Impaired renal function -Psychiatric disorder -Hereditary galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption syndrome.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1.Frequency of Interictal Epileptic Discharges (IEDs) during slow wave sleep (SWS) on active treatment, relative to placebo, as measured by EEG at baseline, the end of treatment period A and the end of treatment period B.
2.Sleep quality (efficiency, number of awakenings, density of sleep spindles and %REM and %SWS on polysomnography) on active treatment relative to placebo, as measured at baseline, the end of treatment period A and the end of treatment period B.
3.Performance on Consolidation of Learning (CoL) tasks on active treatment, relative to placebo, as measured (by validated CoL tools) at baseline, the end of treatment period A and the end of treatment period B.
4.Performance on cognitive assessments including IQ and event related potential (ERP) utilising the commonly employed auditory oddball paradigm as a measure of basic sensory processing and attention as measured at baseline, the end of treatment period A and the end of treatment period B.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. After 6 weeks on treatment A, and 2. (Following the cross-over to treatment B) After 6 weeks on treatment B. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last visit of the last subject will define the end of the trial.
Completion of data analysis and final report to Epilepsy Research UK (the funder) will define the end of the project. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |